Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit due to allegations of deceptive practices related to the promotion and sale of illegitimate versions of the drug Wegovy, resulting in a significant drop in stock price following the termination of its partnership with Novo Nordisk [1][3]. Company Overview - Hims & Hers is a telehealth company that offers prescription medications, over-the-counter medications, and personal care products [2]. - The company announced a collaboration with Novo Nordisk on April 29, 2025, to sell a bundled offering of Wegovy on its platform [2]. Legal Allegations - The class action lawsuit alleges that Hims & Hers and its executives made false or misleading statements and failed to disclose the risks associated with their practices, which jeopardized patient safety [2]. - Novo Nordisk terminated its partnership with Hims & Hers on June 23, 2025, citing deceptive promotion and selling of illegitimate versions of Wegovy [3]. Stock Impact - Following the announcement of the termination of the partnership, Hims & Hers' stock price fell by more than 34% [3]. Class Action Process - Investors who purchased Hims & Hers securities during the specified class period can seek appointment as lead plaintiff in the lawsuit, which allows them to represent the interests of all class members [4].

Core Insights - Hims & Hers Health, Inc. (HIMS) is transforming health and wellness through a consumer-first digital platform, providing treatment for chronic and sensitive conditions, and has conducted over 30 million telehealth consultations in the U.S. and U.K. [1][7] Company Overview - HIMS offers accessible care for mental health, dermatology, sexual wellness, and weight management via its mobile app [7] - The company is expanding its services to include lab testing, compounded medications, and personalized digital wellness solutions [7] Industry Trends - According to McKinsey's 2025 Future of Wellness Trends survey, wellness is increasingly important to consumers, especially Gen Z and millennials, leading to a demand for accessible, science-backed, and personalized solutions [3] - Hims & Hers is well-positioned in the evolving wellness industry with a scalable, tech-enabled model that emphasizes individualized care and proactive health management [3] Competitive Landscape - LifeMD, Inc. (LFMD) focuses on direct-to-patient telehealth services for lifestyle and chronic health conditions, expanding its offerings in accessible digital healthcare [4] - Medifast, Inc. (MED) emphasizes lifestyle-based weight management through its OPTAVIA program, supporting over 25,000 active coaches and impacting over 3 million lives [5] Financial Performance - HIMS shares have increased by 90.6% year-to-date, significantly outperforming the industry growth of 9.9% [6] - The Zacks Consensus Estimate predicts a 174.1% increase in HIMS' earnings per share from 2024 to 2025 [8] Valuation Metrics - HIMS has a forward 12-month price-to-sales (P/S) ratio of 4.1X, which is lower than the industry average of 5.8X but higher than its three-year median of 2.3X [10]

Core Viewpoint - The article emphasizes the importance of value investing and highlights Molina Healthcare (MOH) as a strong candidate for value investors due to its favorable financial metrics and Zacks Rank [2][4][6]. Company Analysis - Molina Healthcare (MOH) currently holds a Zacks Rank of 2 (Buy) and an A grade for Value, indicating strong potential for value investors [4]. - The stock has a Forward P/E ratio of 9.13, significantly lower than the industry average of 11.67, suggesting it may be undervalued [4]. - Over the past year, MOH's Forward P/E has fluctuated between a high of 14.07 and a low of 9.11, with a median of 12.14, indicating volatility but also potential for recovery [4]. - The PEG ratio for MOH is 0.75, compared to the industry average of 1.09, further supporting the notion that the stock is undervalued relative to its expected earnings growth [5]. - MOH's PEG ratio has ranged from a high of 1.24 to a low of 0.75 over the past year, with a median of 1.00, reflecting its growth potential [5]. - The combination of these metrics suggests that MOH is an impressive value stock at the moment, bolstered by a strong earnings outlook [6].

Market Overview - The global healthcare ERP market was valued at USD 7.99 billion in 2024 and is projected to reach approximately USD 16.06 billion by 2034, indicating significant growth driven by the demand for data analysis and management of patient records [1] - North America held a dominant market share of 37% in 2024, while the Asia Pacific region is expected to experience the fastest growth during the forecast period [6][23] Key Drivers of Growth - The increasing need for operational efficiency and data-driven decision-making in healthcare organizations is a primary driver for the growth of the healthcare ERP market [7] - Government initiatives supporting the adoption of digital healthcare technologies and the rising use of electronic health records are also contributing to market expansion [8] Market Segmentation By Function - The finance & billing segment dominated the market in 2024, driven by the need for improved efficiency and reduced errors in financial management [27] - The inventory & material management segment is anticipated to grow the fastest during the forecast period due to its critical role in optimizing operations [28] By Deployment - The on-premises segment led the market in 2024, as organizations prefer managing data within their own infrastructure for better privacy and accessibility [30] - The cloud segment is expected to witness the highest growth rate, driven by demand for flexibility and cost-effectiveness [32] By End Use - Hospitals represented the largest segment in 2024, utilizing ERP systems for efficient data management and operational accessibility [34] - The clinic segment is projected to experience significant growth, driven by the need for integrated software systems to streamline operations [36] Emerging Trends - There is a growing trend towards enhancing patient care through improved patient management systems that streamline data accessibility [9] - The integration of AI in healthcare ERP systems is becoming increasingly important for accurate data processing and real-time accessibility [10] - Cloud adoption is gaining traction due to its flexibility, cost-effectiveness, and scalability [11] Challenges - The healthcare ERP market faces challenges such as high setup costs, complicated integrations with legacy systems, and resistance to change from users [12] - Addressing these challenges requires careful planning and effective change management strategies [13] Recent Developments - In May 2025, Oracle Health partnered with Cleveland Clinic and G42 to create an AI-driven healthcare delivery platform aimed at enhancing patient outcomes [38] - Samsung launched a 'Health Records' feature within its Health app in India, aligning with the Ayushman Bharat Digital Mission to simplify healthcare management [39] Key Players - Major players in the healthcare ERP market include Oracle, Microsoft, SAP, McKesson, and Infor, which are driving growth through cloud adoption and operational streamlining [17][42]

SAN FRANCISCO, July 7, 2025 /PRNewswire/ -- On July 2, 2025, investors in Centene Corp. (NYSE: CNC) saw the price of their shares of this normally low-volatility stock crash 40%, after the company withdrew its guidance, blaming preliminary discussions and data generated by an independent actuary, Wakely.The unusual circumstances and severe investor reaction has prompted national shareholders rights firm Hagens Berman to open an investigation into whether Centene may have violated the securities laws. The fi ...

Core Viewpoint - Hims & Hers Health, Inc. is facing allegations of deceptive practices related to the promotion and sale of illegitimate versions of Wegovy®, which may jeopardize its collaboration with Novo Nordisk and mislead investors about the company's prospects [2]. Group 1: Allegations and Legal Action - The class period for the allegations against Hims & Hers Health, Inc. is from April 29, 2025, to June 23, 2025 [2]. - Allegations include that Hims engaged in deceptive promotion and selling of illegitimate versions of Wegovy®, risking patient safety [2]. - The complaint suggests that the misleading statements made by the defendants about the company's business and operations lacked a reasonable basis [2]. Group 2: Shareholder Information - Shareholders who purchased shares during the class period are encouraged to register for potential lead plaintiff appointment, with a deadline of August 25, 2025 [3]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's status [3]. - Participation in the case incurs no cost or obligation for shareholders [3]. Group 3: Law Firm's Role - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].

SAN FRANCISCO, July 07, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) , a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the retirement of two long-serving board members, Mark Rubash and Ralph Snyderman, M.D., effective July 7, 2025. Concurrently, Karen McGinnis and Kevin O’Boyle have accepted appointments to the board of directors. Mark Rubash has served on the board since 2016, prior to the company’s ...

Core Viewpoint - A securities class action lawsuit has been filed against Hims & Hers Health, Inc. for alleged misleading statements and failure to disclose critical information during the Class Period from April 29, 2025, to June 23, 2025 [1][2]. Company Summary - Hims & Hers is a telehealth company that offers prescription medications, over-the-counter medications, and personal care products [2]. - The company announced a collaboration with Novo Nordisk A/S on April 29, 2025, which included the sale of Novo Nordisk's FDA-approved Wegovy® on its platform [2]. - The lawsuit claims that Hims & Hers engaged in deceptive practices by promoting and selling illegitimate versions of Wegovy®, jeopardizing patient safety [5]. Legal Allegations - The lawsuit alleges that Hims & Hers made false and/or misleading statements and failed to disclose the risks associated with its collaboration with Novo Nordisk [2][5]. - On June 23, 2025, Novo Nordisk announced the termination of its partnership with Hims & Hers due to these deceptive practices, leading to a significant drop in Hims & Hers' stock price by $18.26 per share, a decline of over 34%, closing at $45.00 per share [2]. Important Dates - The lead plaintiff motion deadline for investors is August 25, 2025 [3].

Core Viewpoint - Edelson Lechtzin LLP is investigating securities fraud claims against Hims & Hers Health, Inc. related to its partnership with Novo Nordisk, which may have misled investors regarding the nature of the collaboration and its implications for the company's stock value [1][4]. Company Overview - Hims & Hers Health, Inc. is a telehealth and online pharmacy company that provides prescription and over-the-counter medications, mental health services, and personal care products through a direct-to-consumer platform in the U.S. and the U.K. [3]. Securities Fraud Claims - The complaint alleges that Hims & Hers made materially false and misleading statements and failed to disclose critical facts about its partnership with Novo Nordisk during the class period from April 29, 2025, to June 23, 2025 [4]. - Specifically, Hims & Hers allegedly engaged in deceptive promotion and sale of Novo Nordisk's Wegovy® weight loss drug, creating a substantial risk of termination of the partnership [4]. Partnership Details - On April 29, 2025, Hims & Hers announced a long-term collaboration with Novo Nordisk, which included the immediate sale of a bundled offering of Wegovy® on its platform [5]. - However, on June 23, 2025, Novo Nordisk terminated the partnership, citing Hims & Hers' failure to comply with legal standards regarding the sale of compounded drugs and deceptive marketing practices that jeopardized patient safety [5]. Stock Impact - Following the termination announcement by Novo Nordisk, Hims & Hers' stock price dropped by $22.24 per share, representing a decline of 34.63%, closing at $41.98 per share on June 23, 2025 [5].

Thanks to Donald Trump's so-called One Big Beautiful Bill Act, access to reproductive health care in the United States just took another devastating hit. The Atlantic is calling it the biggest anti-abortion victory since DOBS. And here's why. Buried in the mega bill is a provision that blocks healthc care nonprofits that offer abortions from receiving Medicaid funds for other services that they provide. So, to be clear, this is not a ban on Medicaid funds being used for abortion. Federal Medicaid funds are ...